Comparison
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 vs 4 Hydroxyphenylacetic Aciduria C1848680
Clinical comparison between 46 XY Disorder OF Sex Development Due TO Isolated 17 20 Lyase Deficiency and 4 Hydroxyphenylacetic Aciduria for differential diagnosis and treatment planning.
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
A rare condition involving deficiency of the 17,20-lyase enzyme needed for androgen synthesis. Affects 46,XY individuals and causes undervirilization. Managed with hormone therapy.
4 Hydroxyphenylacetic Aciduria C1848680
A metabolic disorder where the body cannot properly break down certain amino acids. Typically detected in infancy through screening. Treated with dietary modifications and monitoring.
6 comparison axes
Onset
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
0-0
4 Hydroxyphenylacetic Aciduria C1848680
Variable
Onset patterns differ
Severity
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
severe
4 Hydroxyphenylacetic Aciduria C1848680
moderate
Different severity levels
Chronic
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
Chronic
4 Hydroxyphenylacetic Aciduria C1848680
Chronic
Differing course
Communicable
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
No
4 Hydroxyphenylacetic Aciduria C1848680
No
Different transmission
Body System
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
reproductive
4 Hydroxyphenylacetic Aciduria C1848680
metabolic
Same/different system
Category
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
endocrine
4 Hydroxyphenylacetic Aciduria C1848680
metabolic
Different category
Bottom line
46-xy-disorder-of-sex-development-due-to-isolated-17-20-lyase-deficiency-C5681470 and 4-hydroxyphenylacetic-aciduria-C1848680 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 | 4 Hydroxyphenylacetic Aciduria C1848680 | Discriminating power |
|---|---|---|---|
| Genital development | Undervirilization may be present in 46,XY individuals. | No established genital phenotype is described. | High |
| Metabolic presentation | Not primarily described as an amino-acid breakdown disorder. | Impaired handling of certain amino acids is reported. | High |
| Age at recognition | Source onset is coded as early, but exact timing is not established. | Onset is variable and often considered during infancy screening. | Moderate |
When to favor each condition
Choose 46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 when
46,XY undervirilization with suspected androgen-synthesis defect
The supplied description centers on isolated 17,20-lyase deficiency.
High
Endocrine rather than metabolic category is supported
The source classifies the left condition as endocrine and reproductive.
Moderate
Hormone therapy is being considered
Management is described as hormone therapy, without dose guidance here.
Moderate
Choose 4 Hydroxyphenylacetic Aciduria C1848680 when
Abnormal amino-acid-related metabolic result
The right description concerns impaired breakdown of certain amino acids.
High
Infancy screening raises a metabolic concern
Detection is typically described through infancy screening.
Moderate
Dietary management is the stated approach
Treatment is described as dietary modification and monitoring.
Moderate
How key tests differ
| Test | 46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 | 4 Hydroxyphenylacetic Aciduria C1848680 | Interpretation |
|---|---|---|---|
| Steroid or androgen evaluation | May be used to assess androgen synthesis; exact pattern is not supplied. | No established steroid abnormality is described. | An abnormal result needs specialist confirmation and is not itself a diagnosis. |
| Urine organic-acid or amino-acid studies | Not described as the primary finding. | May show 4-hydroxyphenylacetic acid or related metabolites; cutoffs are not supplied. | Interpret only with clinical context and confirmatory testing. |
| Newborn or infancy screening | Not established as a screening diagnosis in the source. | Typically considered after infancy screening. | Screening flags require diagnostic follow-up. |
Prognosis comparison
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
- Outcome
- Long-term outcome is not established; the source rates severity as severe.
- Factors
- Degree of undervirilization and response to supervised hormone care may matter.
4 Hydroxyphenylacetic Aciduria C1848680
- Outcome
- Outcome is not established; the source rates severity as moderate.
- Factors
- Metabolic control, dietary adherence, and monitoring may influence course.
Time frame: Both are described as chronic, without a defined prognosis interval.
Individual course requires specialist assessment; no mortality data are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Undervirilization-related effects | Possible because androgen synthesis is impaired. Not established by the supplied description. Specific complications and frequency are not provided. |
| Metabolic imbalance | Not the described primary problem. Possible if amino-acid handling remains abnormal. Severity and triggers are not quantified here. |
| Treatment-related burden | Hormone therapy requires ongoing clinical supervision. Diet and monitoring may require sustained adherence. No doses, diets, or outcome rates are established. |
Patient education highlights
- HighDifferent conditions
These conditions affect different systems and should not be treated as interchangeable.
- HighSpecialist interpretation
Abnormal screening or hormone results need clinician review before diagnosis.
- MediumLong-term care
Both are described as chronic and may need ongoing monitoring.